SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 209 filers reported holding SAGE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $201 | -56.1% | 9,744 | 0.0% | 0.00% | -50.0% |
| Q2 2023 | $458 | +12.0% | 9,744 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $409 | +9.9% | 9,744 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $372 | -99.9% | 9,744 | 0.0% | 0.00% | -33.3% |
| Q3 2022 | $382,000 | +21.3% | 9,744 | 0.0% | 0.00% | +50.0% |
| Q2 2022 | $315,000 | -2.5% | 9,744 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $323,000 | -22.2% | 9,744 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $415,000 | -3.9% | 9,744 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $432,000 | -22.0% | 9,744 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $554,000 | -25.5% | 9,744 | -2.0% | 0.00% | -25.0% |
| Q1 2021 | $744,000 | -13.5% | 9,944 | 0.0% | 0.00% | -20.0% |
| Q4 2020 | $860,000 | +72.7% | 9,944 | +22.1% | 0.01% | +25.0% |
| Q3 2020 | $498,000 | -26.5% | 8,144 | -50.0% | 0.00% | +33.3% |
| Q2 2020 | $678,000 | -39.2% | 16,288 | +16.3% | 0.00% | -89.3% |
| Q2 2017 | $1,115,000 | -12.8% | 14,000 | -22.2% | 0.03% | -22.2% |
| Q1 2017 | $1,279,000 | – | 18,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 475,600 | $15,362,000 | 5.31% |
| Integral Health Asset Management, LLC | 412,257 | $13,316,000 | 2.74% |
| Palo Alto Investors LP | 851,409 | $27,501,000 | 2.40% |
| Boxer Capital, LLC | 1,094,000 | $35,336,000 | 2.24% |
| DAFNA Capital Management LLC | 180,306 | $5,824,000 | 1.59% |
| Ikarian Capital, LLC | 250,000 | $8,075,000 | 1.47% |
| Bellevue Group AG | 2,973,178 | $96,034,000 | 1.36% |
| SECTOR GAMMA AS | 118,476 | $3,827,000 | 0.86% |
| Artal Group S.A. | 450,000 | $14,535,000 | 0.78% |
| Diametric Capital, LP | 19,393 | $626,000 | 0.46% |